Formulation and development specialist Quay Pharmaceuticals has expanded its range of outsourcing services with new extrusion and spheronisation equipment for the production of spheroids and pellets
The multipurpose equipment from Caleva will allow Quay to develop both small and larger scale batches of pelletised formulations in line with the requirements of Phase I clinical studies.
Pellet based formulations offer several advantages over standard tablet and capsule dosage forms.
In particular, they enable the production of multi-component systems, where pellets of different release properties can be filled into capsules.
As such, specific targeted in-vitro release profiles can be achieved using this dosage form.
Quay Pharmaceuticals provides a comprehensive outsourcing service for the development and testing of pharmaceutical products, with particular expertise in solid dosage forms, including the design of both conventional and modified release products.
The addition of pellet production to the company's capabilities means Quay is now able to offer a complete development and clinical manufacturing package for solid dosing.
The Caleva machines can produce pellets in sizes from 0.5mm to 2mm diameter, with batch sizes between 10g and 1kg.
"This new equipment provides an important extension to our range of services and means we are ideally placed to offer customers a 'one-stop' service to meet all their formulation and testing needs," said Michael Rubinstein, CEO.
